SCIESCOPUSQ2
CURRENT CANCER DRUG TARGETS
BENTHAM SCIENCE PUBL LTD, United Arab Emirates
CURRENT CANCER DRUG TARGETS is an academic journal published by BENTHAM SCIENCE PUBL LTD (United Arab Emirates). Identifiers: ISSN 1568-0096, eISSN 1873-5576. Indexed in SCIE, SCOPUS. Metrics: JIF 3.5, CiteScore 4.1, SJR 0.722, SNIP 0.44. Subject areas: ONCOLOGY. tlooto lists 2,131 papers from this journal.
CiteScore
4.10
Scopus citation metric
SJR
0.722
SCImago rank
SNIP
0.44
Source normalized impact
Percentage rank
-
JIF percentile rank
Journal profile
- ISSN
- 1568-0096
- eISSN
- 1873-5576
- Abbreviation
- CURR CANCER DRUG TAR
- Publisher
- BENTHAM SCIENCE PUBL LTD
- Country
- United Arab Emirates
Web of Science categories
SCIEONCOLOGY
Scopus ASJC categories
1306 Cancer Research2730 Oncology3002 Drug Discovery3004 Pharmacology
Keywords
Oncology
Papers in this journal
Recent papers
- Homoharringtonine Impedes Migration and Invasion by Inhibiting EphB4/SRI/EMT Signaling and Enhances the Antimetastatic Abilities of Erlotinib in Pancreatic Cancer.
2026
- Spatial Analysis of FAP Gene Expression in Breast Cancer.
2026
- Aurora Kinases as Potential Therapeutic Targets for Tumors with pRB and/or MYCN Dysregulation.
2026
- Natural Product-Based Therapeutic Strategies Targeting Signaling Pathways in Prostate Cancer: A Comprehensive Review.
2026
- Design of Experiments-Based Formulation and Optimization of Oxaliplatin-Loaded Solid Lipid Nanoparticles for the Management of Colorectal Cancer.
2026
Most cited papers
- Luteolin, a flavonoid with potential for cancer prevention and therapy.
2008 · 1,029 citations
- Targeting apoptosis pathways in cancer therapy.
2004 · 972 citations
- The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
2008 · 858 citations
- The Role of Snail in EMT and Tumorigenesis
2013 · 837 citations
- Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
2011 · 768 citations